The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT02312960




Registration number
NCT02312960
Ethics application status
Date submitted
5/12/2014
Date registered
5/12/2014
Date last updated
17/01/2019

Titles & IDs
Public title
Radium-223 Dichloride Long-term Follow-up Program
Scientific title
A Phase 4 Long-term Follow-up Study to Define the Safety Profile of Radium-223 Dichloride
Secondary ID [1] 0 0
2014-002407-25
Secondary ID [2] 0 0
16996
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Neoplasm Metastasis / Bone and Bones 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - Data Collection

Other: Arm 1 - The subjects previously enrolled in a selected radium-223 dichloride feeder trial, their treating health care professional, or caregiver will be contacted in 6-month intervals for follow up and query.


Other interventions: Data Collection
No study treatment will be provided in this long term follow up study.

Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Incidence of radium-223 dichloride related Adverse Events
Timepoint [1] 0 0
Up to 7 years
Primary outcome [2] 0 0
Severity of radium-223 dichloride related Adverse Events - Severity will be measured as per guidelines by Common Terminology Criteria for Adverse Events; Version 4.03 (CTCAE)
Timepoint [2] 0 0
Up to 7 years
Primary outcome [3] 0 0
Incidence of radium-223 dichloride related Serious Adverse Events
Timepoint [3] 0 0
Up to 7 years
Primary outcome [4] 0 0
Incidence of placebo-related Adverse Events
Timepoint [4] 0 0
Up to 7 years
Primary outcome [5] 0 0
Severity of placebo-related Adverse Events
Timepoint [5] 0 0
Up to 7 years
Primary outcome [6] 0 0
Incidence of placebo-related Serious Adverse Events
Timepoint [6] 0 0
Up to 7 years
Primary outcome [7] 0 0
Incidence of leukemia
Timepoint [7] 0 0
Up to 7 years
Primary outcome [8] 0 0
Incidence of myelodysplastic syndrome
Timepoint [8] 0 0
Up to 7 years
Primary outcome [9] 0 0
Incidence of aplastic anemia
Timepoint [9] 0 0
Up to 7 years
Primary outcome [10] 0 0
Incidence of primary bone cancer
Timepoint [10] 0 0
Up to 7 years
Primary outcome [11] 0 0
Incidence of any other new primary malignancy
Timepoint [11] 0 0
Up to 7 years
Primary outcome [12] 0 0
Incidence of bone fractures
Timepoint [12] 0 0
Up to 7 years
Primary outcome [13] 0 0
Incidence of bone-associated events
Timepoint [13] 0 0
Up to 7 years
Primary outcome [14] 0 0
Incidence of febrile neutropenia in subjects who receive cytotoxic chemotherapy
Timepoint [14] 0 0
Up to 7 years
Primary outcome [15] 0 0
Incidence of hemorrhage in subjects who receive cytotoxic chemotherapy
Timepoint [15] 0 0
Up to 7 years

Eligibility
Key inclusion criteria
- Subject was previously enrolled in a selected company sponsored feeder trial, and has
received at least 1 dose of radium 223 dichloride or placebo in the feeder trial
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Not applicable to this follow up study

Study design
Purpose of the study
Other
Allocation to intervention
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 4
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
- Darlinghurst
Recruitment hospital [2] 0 0
- Westmead
Recruitment hospital [3] 0 0
- Box Hill
Recruitment postcode(s) [1] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [2] 0 0
2145 - Westmead
Recruitment postcode(s) [3] 0 0
3128 - Box Hill
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Indiana
Country [4] 0 0
United States of America
State/province [4] 0 0
Louisiana
Country [5] 0 0
United States of America
State/province [5] 0 0
Michigan
Country [6] 0 0
United States of America
State/province [6] 0 0
Nebraska
Country [7] 0 0
United States of America
State/province [7] 0 0
New York
Country [8] 0 0
United States of America
State/province [8] 0 0
Pennsylvania
Country [9] 0 0
Belgium
State/province [9] 0 0
Bruxelles - Brussel
Country [10] 0 0
Belgium
State/province [10] 0 0
Edegem
Country [11] 0 0
Belgium
State/province [11] 0 0
Kortrijk
Country [12] 0 0
Belgium
State/province [12] 0 0
Leuven
Country [13] 0 0
Canada
State/province [13] 0 0
Quebec
Country [14] 0 0
Chile
State/province [14] 0 0
Santiago
Country [15] 0 0
Czechia
State/province [15] 0 0
Praha 2
Country [16] 0 0
France
State/province [16] 0 0
NIMES cedex 9
Country [17] 0 0
France
State/province [17] 0 0
Tours
Country [18] 0 0
France
State/province [18] 0 0
Villejuif
Country [19] 0 0
Germany
State/province [19] 0 0
Baden-Württemberg
Country [20] 0 0
Germany
State/province [20] 0 0
Bayern
Country [21] 0 0
Germany
State/province [21] 0 0
Mecklenburg-Vorpommern
Country [22] 0 0
Germany
State/province [22] 0 0
Nordrhein-Westfalen
Country [23] 0 0
Germany
State/province [23] 0 0
Rheinland-Pfalz
Country [24] 0 0
Germany
State/province [24] 0 0
Sachsen
Country [25] 0 0
Germany
State/province [25] 0 0
Thüringen
Country [26] 0 0
Germany
State/province [26] 0 0
Berlin
Country [27] 0 0
Germany
State/province [27] 0 0
Bremen
Country [28] 0 0
Germany
State/province [28] 0 0
Hamburg
Country [29] 0 0
Germany
State/province [29] 0 0
Magdeburg
Country [30] 0 0
Israel
State/province [30] 0 0
Afula
Country [31] 0 0
Israel
State/province [31] 0 0
Beer Sheva
Country [32] 0 0
Israel
State/province [32] 0 0
Haifa
Country [33] 0 0
Israel
State/province [33] 0 0
Jerusalem
Country [34] 0 0
Israel
State/province [34] 0 0
Kfar Saba
Country [35] 0 0
Israel
State/province [35] 0 0
Petah Tikva
Country [36] 0 0
Israel
State/province [36] 0 0
Ramat Gan
Country [37] 0 0
Israel
State/province [37] 0 0
Tel Aviv
Country [38] 0 0
Italy
State/province [38] 0 0
Emilia-Romagna
Country [39] 0 0
Italy
State/province [39] 0 0
Piemonte
Country [40] 0 0
Japan
State/province [40] 0 0
Hokkaido
Country [41] 0 0
Japan
State/province [41] 0 0
Osaka
Country [42] 0 0
Japan
State/province [42] 0 0
Saitama
Country [43] 0 0
Korea, Republic of
State/province [43] 0 0
Seoul Teugbyeolsi
Country [44] 0 0
Korea, Republic of
State/province [44] 0 0
Busan
Country [45] 0 0
Korea, Republic of
State/province [45] 0 0
Seoul
Country [46] 0 0
Norway
State/province [46] 0 0
Oslo
Country [47] 0 0
Russian Federation
State/province [47] 0 0
Moscow
Country [48] 0 0
Russian Federation
State/province [48] 0 0
Obninsk
Country [49] 0 0
Singapore
State/province [49] 0 0
Singapore
Country [50] 0 0
Spain
State/province [50] 0 0
A Coruña
Country [51] 0 0
Spain
State/province [51] 0 0
Barcelona
Country [52] 0 0
Spain
State/province [52] 0 0
Madrid
Country [53] 0 0
Taiwan
State/province [53] 0 0
Kaohsiung
Country [54] 0 0
Taiwan
State/province [54] 0 0
Taipei
Country [55] 0 0
United Kingdom
State/province [55] 0 0
Cornwall
Country [56] 0 0
United Kingdom
State/province [56] 0 0
Devon
Country [57] 0 0
United Kingdom
State/province [57] 0 0
Nottinghamshire
Country [58] 0 0
United Kingdom
State/province [58] 0 0
Somerset
Country [59] 0 0
United Kingdom
State/province [59] 0 0
South Yorkshire
Country [60] 0 0
United Kingdom
State/province [60] 0 0
Bristol
Country [61] 0 0
United Kingdom
State/province [61] 0 0
Cottingham

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Bayer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Patients will be followed up in this study after prior treatment with BAY 88-8223 /
Radium-223 dichloride / Xofigo .
Trial website
https://clinicaltrials.gov/show/NCT02312960
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Bayer Study Director
Address 0 0
Bayer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Bayer Clinical Trials Contact
Address 0 0
Country 0 0
Phone 0 0
(+)1-888-84 22937
Fax 0 0
Email 0 0
clinical-trials-contact@bayer.com
Contact person for scientific queries

No data has been provided for results reporting
Summary results
Not applicable